MacroGenics' Tebotelimab Study Meets Primary Endpoint
Ticker: MGNX · Form: 8-K · Filed: Apr 8, 2026 · CIK: 0001125345
Sentiment: bullish
Topics: clinical-trial-results, oncology, partnership
Related Tickers: MRK
TL;DR
MGNX tebotelimab + Keytruda combo CRUSHED Phase 2 LINGO-2 study for urothelial carcinoma, met PFS endpoint!
AI Summary
On April 8, 2026, MacroGenics Inc. filed an 8-K report detailing the results of the Phase 2 LINGO-2 study for its drug tebotelimab. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) for patients with advanced or metastatic urothelial carcinoma who received tebotelimab in combination with Merck's Keytruda compared to those receiving Keytruda alone.
Why It Matters
This positive outcome in the LINGO-2 study is a significant step for MacroGenics, potentially paving the way for broader regulatory approval and commercialization of tebotelimab in a key cancer indication.
Risk Assessment
Risk Level: medium — While the study met its primary endpoint, further clinical trials and regulatory review are necessary, and commercial success is not guaranteed.
Key Numbers
- Phase 2 — Study Phase (Indicates the stage of clinical development for tebotelimab in this study.)
Key Players & Entities
- MacroGenics Inc. (company) — Filer of the 8-K report and developer of tebotelimab
- tebotelimab (drug) — Drug developed by MacroGenics, tested in the LINGO-2 study
- LINGO-2 study (study) — Phase 2 clinical trial for tebotelimab
- Merck (company) — Manufacturer of Keytruda, used in combination therapy
- Keytruda (drug) — Drug manufactured by Merck, used in combination with tebotelimab
- advanced or metastatic urothelial carcinoma (disease) — Cancer type studied in the LINGO-2 trial
- April 8, 2026 (date) — Filing date of the 8-K report
FAQ
What was the primary endpoint of the LINGO-2 study?
The primary endpoint was progression-free survival (PFS).
What was the combination therapy tested in the LINGO-2 study?
The combination therapy was tebotelimab with Merck's Keytruda.
What was the comparator arm in the LINGO-2 study?
The comparator arm received Keytruda alone.
What type of cancer was targeted in the LINGO-2 study?
The study targeted patients with advanced or metastatic urothelial carcinoma.
When was this 8-K filing made?
The 8-K filing was made on April 8, 2026.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2026 regarding MACROGENICS INC (MGNX).